🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 15 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
28/02/2020 13,92 15,34 13,65 15,22 +5,55% 12,11% 287.700
27/02/2020 15,00 15,36 13,84 14,42 -5,50% 10,13% 325.300
26/02/2020 15,35 16,66 14,61 15,26 +2,62% 13,36% 289.200
25/02/2020 16,44 16,97 14,76 14,87 -9,55% 13,44% 351.200
24/02/2020 16,82 17,00 15,29 16,44 -5,08% 10,20% 475.800
21/02/2020 15,95 18,44 15,51 17,32 +8,59% 18,37% 765.300
20/02/2020 15,93 16,84 15,35 15,95 +1,33% 9,32% 707.100
19/02/2020 12,73 16,20 12,67 15,74 +26,63% 27,73% 1.563.300
18/02/2020 10,95 12,86 10,95 12,43 +12,69% 17,44% 1.081.700
14/02/2020 11,40 11,40 11,00 11,03 -3,58% 3,51% 53.100
13/02/2020 11,22 11,98 11,07 11,44 +1,60% 8,11% 118.800
12/02/2020 11,58 11,60 10,85 11,26 -1,92% 6,48% 78.100
11/02/2020 11,77 12,00 11,46 11,48 -1,71% 4,59% 73.100
10/02/2020 11,15 11,87 11,05 11,68 +4,38% 7,35% 121.100
07/02/2020 11,24 12,06 11,04 11,19 -1,24% 9,12% 89.400
06/02/2020 11,30 11,40 11,03 11,33 -0,70% 3,32% 84.400
05/02/2020 10,20 11,54 10,18 11,41 +13,99% 13,33% 279.100
04/02/2020 9,43 10,03 9,26 10,01 +8,57% 8,22% 639.600
03/02/2020 9,13 9,49 9,04 9,22 +5,01% 4,98% 1.151.000
31/01/2020 8,99 9,04 8,55 8,78 -3,52% 5,45% 102.100
30/01/2020 9,01 9,18 8,90 9,10 -0,22% 3,05% 45.700
29/01/2020 9,65 9,71 9,06 9,12 -5,69% 6,74% 53.900
28/01/2020 9,76 9,95 9,60 9,67 +0,21% 3,59% 235.500
27/01/2020 9,14 10,18 9,13 9,65 +2,88% 11,49% 83.500
24/01/2020 9,49 9,63 9,16 9,38 -0,85% 4,95% 78.800
23/01/2020 9,83 9,90 9,23 9,46 -4,92% 6,82% 115.300
22/01/2020 10,10 10,48 9,90 9,95 -0,70% 5,74% 126.000
21/01/2020 10,13 10,38 9,84 10,02 -2,05% 5,33% 72.300
17/01/2020 10,65 10,70 10,16 10,23 -2,20% 5,07% 82.100
16/01/2020 10,50 10,80 10,35 10,46 +0,97% 4,29% 143.700